Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review.
Sara Rahavi-EzabadiSheng ZhouStella E LeeElisabeth FerenceAnthony MagitShelby LeuinKawthar MohamedNima RezaeiVijay A PatelPublished in: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2024)
For children with atopic dermatitis, asthma, and chronic idiopathic urticaria, biologic therapies such as Omalizumab, Dupilumab, and Mepolizumab have gained Food and Drug Administration approval. The role of biologic therapy in pediatric CRSwNP demonstrates significant promise in the comprehensive management of the unified airway. Additional Phase III trials are necessary to broaden clinical indications for children with comorbid conditions and complex sinonasal disease.
Keyphrases
- atopic dermatitis
- drug administration
- rheumatoid arthritis
- phase iii
- chronic rhinosinusitis
- young adults
- open label
- clinical trial
- chronic obstructive pulmonary disease
- lung function
- stem cells
- machine learning
- double blind
- human health
- mesenchymal stem cells
- air pollution
- risk assessment
- climate change
- study protocol
- smoking cessation
- replacement therapy
- deep learning
- drug induced